Vigabatrin
- PMID:17199033
- PMCID: PMC7479688
- DOI: 10.1016/j.nurt.2006.11.008
Vigabatrin
Abstract
Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30-50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65 degrees of lateral vision (normal, 90 degrees). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.
Similar articles
- Vigabatrin: 2008 update.Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD.Willmore LJ, et al.Epilepsia. 2009 Feb;50(2):163-73. doi: 10.1111/j.1528-1167.2008.01988.x.Epilepsia. 2009.PMID:19230067Review.
- A controlled study of vigabatrin and visual abnormalities.Manuchehri K, Goodman S, Siviter L, Nightingale S.Manuchehri K, et al.Br J Ophthalmol. 2000 May;84(5):499-505. doi: 10.1136/bjo.84.5.499.Br J Ophthalmol. 2000.PMID:10781514Free PMC article.
- [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].Gross-Tsur V, Lahat E, Banin E, Shahar E, Shalev R.Gross-Tsur V, et al.Harefuah. 2002 Mar;141(3):247-9, 315.Harefuah. 2002.PMID:11944216Hebrew.
- Balancing clinical benefits of vigabatrin with its associated risk of vision loss.Pellock JM.Pellock JM.Acta Neurol Scand Suppl. 2011;(192):83-91. doi: 10.1111/j.1600-0404.2011.01603.x.Acta Neurol Scand Suppl. 2011.PMID:22061183Review.
- Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.Krauss G, Faught E, Foroozan R, Pellock JM, Sergott RC, Shields WD, Ziemann A, Dribinsky Y, Lee D, Torri S, Othman F, Isojarvi J.Krauss G, et al.Epilepsy Behav. 2016 Mar;56:15-9. doi: 10.1016/j.yebeh.2015.12.004. Epub 2016 Jan 22.Epilepsy Behav. 2016.PMID:26807550
Cited by
- Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I.Melhado EM, Santos PSF, Kaup AO, Costa ATNMD, Roesler CAP, Piovesan ÉJ, Sarmento EM, Theotonio GOM, Campos HC, Fortini I, Souza JA, Maciel Júnior JA, Segundo JBA, Carvalho JJF, Speziali JG, Calia LC, Barea LM, Queiroz LP, Souza MNP, Figueiredo MRCF, Costa MENM, Peres MFP, Jurno ME, Peixoto PM, Kowacs PA, Rocha-Filho PAS, Moreira Filho PF, Silva-Neto RP, Fragoso YD.Melhado EM, et al.Arq Neuropsiquiatr. 2022 Aug;80(8):845-861. doi: 10.1055/s-0042-1756441. Epub 2022 Oct 17.Arq Neuropsiquiatr. 2022.PMID:36252594Free PMC article.
- Treatment of refractory complex partial seizures: role of vigabatrin.Waterhouse EJ, Mims KN, Gowda SN.Waterhouse EJ, et al.Neuropsychiatr Dis Treat. 2009;5:505-15. doi: 10.2147/ndt.s5236. Epub 2009 Oct 12.Neuropsychiatr Dis Treat. 2009.PMID:19851518Free PMC article.
- The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways.Amer RM, Eltokhy AK, Elesawy RO, Barakat AN, Basha E, Eldeeb OS, Aboalsoud A, Elgharabawy NM, Ismail R.Amer RM, et al.Molecules. 2022 Jun 7;27(12):3659. doi: 10.3390/molecules27123659.Molecules. 2022.PMID:35744783Free PMC article.
- Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase.Zhu W, Doubleday PF, Butrin A, Weerawarna PM, Melani RD, Catlin DS, Dwight TA, Liu D, Kelleher NL, Silverman RB.Zhu W, et al.J Am Chem Soc. 2021 Jun 2;143(21):8193-8207. doi: 10.1021/jacs.1c03572. Epub 2021 May 20.J Am Chem Soc. 2021.PMID:34014654Free PMC article.
- Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.Dragas R, Westall C, Wright T.Dragas R, et al.Doc Ophthalmol. 2014 Oct;129(2):97-104. doi: 10.1007/s10633-014-9453-y. Epub 2014 Jul 10.Doc Ophthalmol. 2014.PMID:25008578
References
- Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 2004;3:618–621. - PubMed
- Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia. 1999;40:445–452. - PubMed
- Forsgren L, Bucht G, Eriksson S, Bergmark L. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia. 1996;37:224–229. - PubMed
- Murro AM. Complex partial seizures [Internet]. Updated: December 5, 2005. Accessed July 5, 2006. Available at http://www.emedicine.com/NEURO/topic74.htm.
- Elterman RD, Shields WD, Mansfield KA, Nakagawa J. US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57:1416–1421. - PubMed